New York Health News

E-mail

Close Window E-mail This Page

FDA Approves Shire's ADHD Drug Vyvanse

Required fields are marked with an asterisk(*)

Recipient E-mail:*
- Your Name:*
- Your E-mail:*
Add a Message:
Send me a copy of this e-mail.

Type the characters in this picture:*

Click here to refresh with new letters

The information you provide will be used only to send the requested e-mail and will not be used to send any other e-mail communications. Read more in our Privacy Policy

Send E-mail

Print Share + Comments

Feb 23, 2007 3:52 pm US/Eastern

FDA Approves Shire's ADHD Drug Vyvanse

WASHINGTON (AP) ―

Click to enlarge 1 of 1: The Food and Drug Administration approved Vyvanse to treat ADHD.
CBS

Close

numSlides of totalImages

The government has approved an amphetamine-based drug to treat attention deficit hyperactivity disorder that its manufacturer says is harder to abuse than older stimulants.

The Food and Drug Administration approved Vyvanse, also known as lisdexamfetamine, spokeswoman Susan Cruzan said. The drug is made by Shire PLC.

Shire hopes the drug will extend its lucrative ADHD franchise once its top-selling Adderall XR begins facing competition from lower-priced generic versions in 2009. Shire plans to move patients from the older to the newer drug at the time, company spokesman Matt Cabrey said this week.